Breaking News

Takeda to Invest $30B into U.S. Operations

Joins a league of pharma companies increasing investments in the U.S.

Author Image

By: Charlie Sternberg

Associate Editor

Takeda’s Cambridge, MA global hub.

Takeda is the latest major pharmaceutical company to increase its investments in the U.S. market, partly in response to President Donald Trump’s potential tariffs. The company’s CEO, Christophe Weber, announced on Thursday, during the company’s earnings call, that Takeda will be investing approximately $30 billion into its U.S. operations over the next five years. “This reflects the fact that the U.S. is the world’s leading market for biopharmaceutical innovation, and I hope that will continu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters